Management of psoriasis patients with hepatitis B or hepatitis C virus infection.
The systemic therapies available for the management of Psoriasis (PsO) patients who cannot be treated with more conservative options, such as topical agents and/or phototherapy, with the exception of acitretin, can worsen or reactivate a chronic infection. Therefore, before administering immunosuppressive therapies with either conventional disease-modifying drugs (cDMARDs) or biological ones (bDMARDs) it is mandatory to screen patients for some infections, including hepatitis B virus (HBV) and hepatitis C virus (HCV). In particular, the patients eligible to receive an immunosuppressive drug must be screened for the following markers: antibody to hepatitis B core, antibody to hepatitis B surface antigen (anti-HBsAg), HBsAg, and antibody to HCV (anti-HCV). In case HBV or HCV infection is diagnosed, a close collaboration with a consultant hepatologist is needed before and during an immunosuppressive therapy. Concerning therapy with immunosuppressive drugs in PsO patients with HBV or HCV infection, data exist mainly for cyclosporine a (CyA) or bDMARDs (etanercept, adalimumab, infliximab, ustekinumab). The natural history of HBV and HCV infection differs significantly as well as the effect of immunosuppression on the aforementioned infectious diseases. As a rule, in the case of active HBV infection, systemic immunosuppressive antipsoriatic therapies must be deferred until the infection is controlled with an adequate antiviral treatment. Inactive carriers need to receive antiviral prophylaxis 2-4 wk before starting immunosuppressive therapy, to be continued after 6-12 mo from its suspension. Due to the risk of HBV reactivation, these patients should be monitored monthly for the first 3 mo and then every 3 mo for HBV DNA load together with transaminases levels. Concerning the patients who are occult HBV carriers, the risk of HBV reactivation is very low. Therefore, these patients generally do not need antiviral prophylaxis and the sera HBsAg and transaminases dosing can be monitored every 3 mo. Concerning PsO patients with chronic HCV infection their management with immunosuppressive drugs is less problematic as compared to those infected by HBV. In fact, HCV reactivation is an extremely rare event after administration of drugs such as CyA or tumor necrosis factor-α inhibitors. As a rule, these patients can be monitored measuring HCV RNA load, and ALT, aspartate transaminase, gamma-glutamyl-transferase, bilirubin, alkaline phosphatase, albumin and platelet every 3-6 mo. The present article provides an updated overview based on more recently reported data on monitoring and managing PsO patients who need systemic antipsoriatic treatment and have HBV or HCV infection as comorbidity.
Claudio Bonifati, Viviana Lora, Dario Graceffa, Center for the Study and Treatment of Psoriasis San Gallicano Dermatologic Institute, IRCCS, 00144 Rome, Italy.
Claudio
C
Bonifati
Claudio Bonifati, Viviana Lora, Dario Graceffa, Center for the Study and Treatment of Psoriasis San Gallicano Dermatologic Institute, IRCCS, 00144 Rome, Italy.
Viviana
V
Lora
Claudio Bonifati, Viviana Lora, Dario Graceffa, Center for the Study and Treatment of Psoriasis San Gallicano Dermatologic Institute, IRCCS, 00144 Rome, Italy.
Dario
D
Graceffa
Claudio Bonifati, Viviana Lora, Dario Graceffa, Center for the Study and Treatment of Psoriasis San Gallicano Dermatologic Institute, IRCCS, 00144 Rome, Italy.
Lorenzo
L
Nosotti
D018501:Antirheumatic Agents / Q000627:therapeutic use*; D000998:Antiviral Agents / Q000627:therapeutic use*; D015897:Comorbidity; D003879:Dermatologic Agents / Q000627:therapeutic use*; D019468:Disease Management; D006510:Hepatitis B Antibodies / Q000276:immunology; D006514:Hepatitis B Surface Antigens; D019694:Hepatitis B, Chronic / Q000175:diagnosis / Q000188:drug therapy* / Q000453:epidemiology / Q000276:immunology; D018937:Hepatitis C Antibodies / Q000276:immunology; D019698:Hepatitis C, Chronic / Q000175:diagnosis / Q000188:drug therapy* / Q000453:epidemiology / Q000276:immunology; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008403:Mass Screening; D011565:Psoriasis / Q000188:drug therapy* / Q000453:epidemiology; D014775:Virus Activation
D018501:Antirheumatic Agents; D000998:Antiviral Agents; D003879:Dermatologic Agents; D006510:Hepatitis B Antibodies; D006514:Hepatitis B Surface Antigens; D018937:Hepatitis C Antibodies; D007166:Immunosuppressive Agents
Biological disease-modifying drugs; Conventional disease-modifying drugs; Hepatitis B virus infection; Hepatitis C virus infection; Psoriasis; Therapy